ArticleCancer medicine2022

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.

Cameron Chalker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.